Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
|
|
MEMORY PHARMACEUTICALS CORP (MEMY)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/13/2008 |
8-K
| Quarterly results |
| 08/13/2008 |
8-K
| Quarterly results |
| 05/14/2008 |
8-K
| Quarterly results |
| 03/06/2008 |
8-K
| Quarterly results |
| 11/08/2007 |
8-K
| Quarterly results |
| 08/09/2007 |
8-K
| Quarterly results |
| 05/10/2007 |
8-K
| Quarterly results|
Docs:
|
"Memory Pharmaceuticals Reports First Quarter 2007 Financial Results MONTVALE, N.J., May 10, 2007/PR Newswire — First Call/ — Memory Pharmaceuticals Corp. , a biopharmaceutical company focused on the discovery and development of innovative drug candidates for the treatment of a broad range of central nervous system conditions, today reported its financial results for the three months ended March 31, 2007. “Our clinical objectives for 2007 include the completion of our ongoing proof-of-concept trials for MEM 1003 and MEM 3454, and we've made good progress during the first quarter of 2007 toward achieving these objectives,” said Jim Sulat, President and Chief Executive Officer. “Since the beginning of the year, we've initiated our Phase 2a Alzheimer's disease trial for MEM 3454, and we recent..." |
|
| 02/22/2007 |
8-K
| Quarterly results |
| 11/09/2006 |
8-K
| Quarterly results|
Docs:
|
"Memory Pharmaceuticals Reports Third Quarter 2006 Financial Results MONTVALE, N.J., November 9, 2006 — Memory Pharmaceuticals Corp. , a biopharmaceutical company focused on the discovery and development of innovative drug candidates for the treatment of a broad range of central nervous system conditions, today reported its financial results for the three and nine months ended September 30, 2006. “Over the past few months, we have strengthened our financial position and reported important advancements with our clinical program for MEM 1003 and our other preclinical programs,” said Jim Sulat, President and Chief Executive Officer. “As a result of continued progress with our preclinical programs, we achieved key milestones and secured research funding commitments for 2007 from our partners, w..." |
|
| 08/09/2006 |
8-K
| Quarterly results|
Docs:
|
"Memory Pharmaceuticals Reports Second Quarter 2006 Financial Results MONTVALE, N.J., August 9, 2006 — Memory Pharmaceuticals Corp. , a biopharmaceutical company focused on the discovery and development of innovative drug candidates for the treatment of a broad range of central nervous system conditions, today reported its financial results for the three and six months ended June 30, 2006. “Since the beginning of the year, we have focused on advancing our clinical stage pipeline into important proof-of-concept studies. We are progressing our Phase 2a trial for MEM 1003 in Alzheimer's disease, we expect to begin dosing in a Phase 2a trial for that same drug candidate in bipolar disorder shortly, and our goal is to initiate a Phase 2a trial for MEM 3454, our lead nicotinic alpha-7 partial ago..." |
|
|
|